Apixaban in Thrombocytopenia

EARLY_PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 28, 2025

Primary Completion Date

July 1, 2026

Study Completion Date

July 1, 2028

Conditions

Deep Vein ThrombosisPulmonary Embolism and ThrombosisThrombocytopeniaRecurrent Venous Thromboembolism

Interventions

DRUG

Apixaban

A factor Xa inhibitor, 2.5 and 5 mg tablets, by mouth per protocol.

Trial Locations (1)

RECRUITING

Beth Israel Deaconess Medical Center, Boston

All Listed Sponsors

lead

Rushad Patell

OTHER